Table of Content

1. Executive Summary
1.1. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Disease Type Lifecycle Analysis
2.4. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Disease Type
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Disease Type, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
3.3.3.1. Acute ITP
3.3.3.2. Chronic
3.3.3.3. Others
3.4. Market Attractiveness Analysis: Disease Type
3.5. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Product
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
3.5.3.1. Corticosteroids
3.5.3.2. IVIG
3.5.3.3. Anti-D Immunoglobulins
3.5.3.4. TPO-RA
3.5.3.5. Others
3.6. Market Attractiveness Analysis: Product
4. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Disease Type
5.3.3. By Product
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
5.5.1. Acute ITP
5.5.2. Chronic
5.5.3. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
5.6.1. Corticosteroids
5.6.2. IVIG
5.6.3. Anti-D Immunoglobulins
5.6.4. TPO-RA
5.6.5. Others
5.7. Market Attractiveness Analysis
6. Europe Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Disease Type
6.3.3. By Product
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
6.5.1. Acute ITP
6.5.2. Chronic
6.5.3. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
6.6.1. Corticosteroids
6.6.2. IVIG
6.6.3. Anti-D Immunoglobulins
6.6.4. TPO-RA
6.6.5. Others
6.7. Market Attractiveness Analysis
7. East Asia Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Disease Type
7.3.3. By Product
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
7.5.1. Acute ITP
7.5.2. Chronic
7.5.3. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
7.6.1. Corticosteroids
7.6.2. IVIG
7.6.3. Anti-D Immunoglobulins
7.6.4. TPO-RA
7.6.5. Others
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Disease Type
8.3.3. By Product
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
8.5.1. Acute ITP
8.5.2. Chronic
8.5.3. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
8.6.1. Corticosteroids
8.6.2. IVIG
8.6.3. Anti-D Immunoglobulins
8.6.4. TPO-RA
8.6.5. Others
8.7. Market Attractiveness Analysis
9. Latin America Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Product
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
9.5.1. Acute ITP
9.5.2. Chronic
9.5.3. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
9.6.1. Corticosteroids
9.6.2. IVIG
9.6.3. Anti-D Immunoglobulins
9.6.4. TPO-RA
9.6.5. Others
9.7. Market Attractiveness Analysis
10. Middle East & Africa Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Product
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Type, 2023 - 2030
10.5.1. Acute ITP
10.5.2. Chronic
10.5.3. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
10.6.1. Corticosteroids
10.6.2. IVIG
10.6.3. Anti-D Immunoglobulins
10.6.4. TPO-RA
10.6.5. Others
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Analog IC
11.2.3. Apparent Disease Type Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Amgen Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Disease Type
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. F. Hoffmann-La Roche Ltd
11.3.2.1. Overview
11.3.2.2. Segments and Disease Type
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Grifols, S.A.
11.3.3.1. Overview
11.3.3.2. Segments and Disease Type
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. GSK plc.;
11.3.4.1. Overview
11.3.4.2. Segments and Disease Type
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Shangxian Minimal Invassive Inc.
11.3.5.1. Overview
11.3.5.2. Segments and Disease Type
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. INTROMEDIC
11.3.6.1. Overview
11.3.6.2. Segments and Disease Type
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Medtronic
11.3.7.1. Overview
11.3.7.2. Segments and Disease Type
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. FUJIFILM Holdings Corporation
11.3.8.1. Overview
11.3.8.2. Segments and Disease Type
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Olympus Corporation
11.3.9.1. Overview
11.3.9.2. Segments and Disease Type
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. JINSHAN Science & Technology (Group) Co., Ltd
11.3.10.1. Overview
11.3.10.2. Segments and Disease Type
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations